Supplemental Digital Content 1. List of study exclusion and inclusion criteria.
Exclusion Criteria











Animal or in vitro studies
Case reports, letters, comments, editorials, and reviews
Studies published in languages other than English, French, German, Italian, or Spanish
Studies published before 1990
Studies with fewer than 10 patients per study group (prophylaxed or non-prophylaxed or
with RSV)
Studies in pediatric patients with average age older than 24 months at enrollment
Studies not reporting outcomes of interest (no mortality or hospital morbidity)
Studies selecting all infants with HIV, cystic fibrosis, or immunodeficiency
Studies reporting only incidence of acute otitis media and no other outcomes of interest
For prophylaxis studies:
 Studies with all infants on pharmacologic prophylaxis other than palivizumab or
motavizumab and no control arm
 Studies of mixed (prophylaxed and nonprophylaxed) infants with no separable
outcomes for each group
 Epidemiologic studies reporting only incidence of RSV infection and no other
outcomes of interest
 Studies of prophylaxed infants with follow-up duration less than 150 days or less than
one RSV season.
For RSV treatment studies:
 Studies of investigational treatment of RSV infection (ie, ribavirin) with no control
(or standard of care) group
 Studies selecting only for surviving first season infants
 Studies selecting all patients for infections other than RSV
 Studies selecting all patients with co-infections (ie, RSV and influenza, RSV and
pertussis, etc.) and report outcomes for coinfections without sole RSV infection
comparator
 Studies of a mix of patients with various infections and no outcomes reported
separately for RSV-infected patients
 Studies of RSV infants not reporting mortality
Inclusion Criteria
 Studies reporting RSV-related clinical and/or use outcomes in any of the following infant
populations:
 Pre-term high risk:
 Premature infants (< 37 wGA and study entry age of 24 months)
 Infants and children with age at study entry 24 months and with CLD and/or
CHD
 Full-term high risk infants with any of the following conditions:
 Solid organ transplant
 Bone marrow transplant
 Vent-dependent infants



 Congenital diaphragmatic hernia
 Sickle cell disease
 Down’s syndrome.
Full-term infants/other
Mixed infant population (ie, full-term, pre-term, healthy, high-risk, etc.)
Clinical and utilization outcomes of interest included
 Mortality
 Hospitalizations
 ICU admissions
 Use of mechanical ventilation
 Apnea episodes
 Acute otitis media
 Oxygen requirements
 Apparent life-threatening events
 Resuscitations
 Outpatient visits
 ED admissions